Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia

In adults with non-promyelocytic acute myeloid leukemia (AML), high-dose cytarabine consolidation therapy has been shown to influence survival in selected patients, although the appropriate doses and schemes have not been defined. We evalua...

Full description

Bibliographic Details
Main Authors:	M.C. Azevedo, E.D.R.P. Velloso, V. Buccheri, D.A.F. Chamone, P.E. Dorlhiac-Llacer
Format:	Article
Language:	English
Published:	Associação Brasileira de Divulgação Científica 2015-02-01
Series:	Brazilian Journal of Medical and Biological Research
Subjects:	Acute myeloid leukemia Chemotherapy Consolidation therapy High-dose cytarabine Prognosis
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000200178&lng=en&tlng=en

Similar Items

Toxicity and outcome of adults with acute myeloid leukemia receiving consolidation with high-dose cytarabine
by: Lais Moreira Lopes, et al.
Published: (2024-10-01)

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: Shahriari Ahmadi A, et al.
Published: (2004-08-01)

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: A Shahriari Ahmadi, et al.
Published: (2004-03-01)

Standard dose Cytarabine-Induced Encephalopathy in an Acute Myeloid Leukemia Patient: A Case Report
by: Mehrshad Ebrahimpour, et al.
Published: (2024-10-01)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
by: Baohang Zhang, et al.
Published: (2023-05-01)

High-dose cytarabine monotherapy is superior to standard-dose cytarabine- based multiagent sequential treatment cycle for consolidation treatment in adult (14-59 years) AML patients according to European Leukemia Net 2022 risk stratification
by: Xiaoyu Wang, et al.
Published: (2023-01-01)

Enhanced Antitumor Efficacy of Cytarabine and Idarubicin in Acute Myeloid Leukemia Using Liposomal Formulation: In Vitro and In Vivo Studies
by: Chunxia Zhu, et al.
Published: (2024-09-01)

Glucose Metabolism as a Potential Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia
by: Joana Pereira-Vieira, et al.
Published: (2024-03-01)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
by: Louise Laloi, et al.
Published: (2023-03-01)

Corneal epithelial microcysts due to high dose Cytarabine administration in acute myeloid leukemia
by: Tuba Hilkay Karapınar, et al.
Published: (2012-03-01)

Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse‐risk acute myeloid leukaemia: A single‐centre retrospective analysis
by: Bao‐Quan Song, et al.
Published: (2023-11-01)

TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE
by: Maël Heiblig, et al.
Published: (2016-01-01)

Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling
by: Qiong Su, et al.
Published: (2023-12-01)

Validation of CRISPR targeting for proliferation and cytarabine resistance control genes in the acute myeloid leukemia cell line MOLM-13
by: Subhash C Prajapati, et al.
Published: (2022-03-01)

Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia
by: Tomislav Smoljo, et al.
Published: (2023-10-01)

Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients
by: Gökçen Özcan, et al.
Published: (2021-04-01)

Diffuse purpuric eruption in a patient with acute myeloid leukemia
by: Zoha K. Momin, BS, et al.
Published: (2023-11-01)

Interaction of Lipophilic Cytarabine Derivatives with Biomembrane Model at the Air/Water Interface
by: Jhon Fernando Berrio Escobar, et al.
Published: (2022-09-01)

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
by: Lauro Fabián Amador-Medina, et al.
Published: (2024-12-01)

Applicable pharmacokinetic study: Development and validation of bioanalytical LC-MS/MS method for the simultaneous quantification of cytarabine and glasdegib used for the treatment of acute myeloid leukemia
by: Abdulaziz Alnasser, et al.
Published: (2023-10-01)

Concanavalin A staining: a potential biomarker to predict cytarabine sensitivity in acute myeloid leukemia
by: Tao Zhang, et al.
Published: (2024-01-01)

Case report: Dysphonia associated with high-dose cytarabine therapy
by: Ling Ma, et al.
Published: (2025-01-01)

High dose cytarabine induced myopericarditis: When the heart debilitates but the fight against cancer must be strong
by: Villa-Saldarriaga, María P, et al.
Published: (2022-04-01)

Bilosomes and Niosomes for Enhanced Intestinal Absorption and In Vivo Efficacy of Cytarabine in Treatment of Acute Myeloid Leukemia
by: Abdelrahman R. Said, et al.
Published: (2024-11-01)

Can pharmacogenetics impact the therapeutic effect of cytarabine and anthracyclines in adult acute myeloid leukaemia patients?: A Serbian experience
by: Pravdić Zlatko, et al.
Published: (2024-01-01)

Enterotoxins A and B produced by Staphylococcus aureus increase cell proliferation, invasion and cytarabine resistance in acute myeloid leukemia cell lines
by: Seyhan Turk, et al.
Published: (2023-09-01)

Prognostication refinement in NPM1‐mutated acute myeloid leukemia stratified by FLT3‐ITD status with different induction doses of cytarabine
by: Biao Wang, et al.
Published: (2023-04-01)

Chemotherapy-Induced Survivin Regulation in Acute Myeloid Leukemia Cells
by: Petra Otevřelová, et al.
Published: (2021-01-01)

The histological changes induced by Cytarabine on rabbits livers (with and without vitamin E administration)
by: Saif Al-Jammas, et al.
Published: (2020-01-01)

Physiological and histological effects of apigenin and luteolin on Cytarabine injected rats
by: Ghada A. Taqa, et al.
Published: (2024-01-01)

Advanced Photocatalytic Degradation of Cytarabine from Pharmaceutical Wastewaters
by: Alexandra Berbentea, et al.
Published: (2024-05-01)

Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis
by: Yang Qiu, et al.
Published: (2024-04-01)

Cytarabine Induced Reproductive Histopathological Changes in Albino Male Mice
by: Niran A. Ibrahim, et al.
Published: (2017-01-01)

Intake of oligoelements with cytarabine or etoposide alters dopamine levels and oxidative damage in rat brain
by: David Calderón Guzmán, et al.
Published: (2024-05-01)

Pharmacogenetics of ABCB1, CDA, DCK, GSTT1, GSTM1 and outcomes in a cohort of pediatric acute myeloid leukemia patients from Colombia
by: Luz K. Yunis, et al.
Published: (2023-03-01)

Whole-cell biosynthesis of cytarabine by an unnecessary protein-reduced Escherichia coli that coexpresses purine and uracil phosphorylase
by: Li, Ping, et al.
Published: (2022)

Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial
by: Richard Dillon, et al.
Published: (2022-11-01)

Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
by: Álvaro Pinto-Merino, et al.
Published: (2022-03-01)

Cladribine and cytarabine in children refractory high risk multisystem Langerhans cell histiocytosis
by: Wenqian Wang, et al.
Published: (2023-09-01)

Third cranial nerve palsy: An unusual presentation of cytarabine toxicity
by: Suchismita Mishra, et al.
Published: (2023-01-01)